# Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

> **NCT05803135** · PHASE4 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 138 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Iguratimod combined with Tofacitinib;

## Key facts

- **NCT ID:** NCT05803135
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-31
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2023-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05803135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05803135, "Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05803135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*